Table 2. Median survival of intracranial breast cancer model.

Treatment Groups	Dose(mg/kg)	Mice per group	Median Survival and 95% CI(days)	P value (compared to control)*
Control (PBS)	N/A	33	26 (25 – 28)	N/A
NonL-doxo	6mg/kg IV	20	23.5 (18 – 28)	0.26
PLD	6mg/kg IV	20	32 (31 – 38)	0.0012
ABT-888	25m/kg OG	18	27 (24 – 31)	0.5
NonL-doxo plus ABT-888	4.5mg/kg IV and 25mg/kg OG	36	29.5 (25 – 34)	0.04
PLD plus ABT-888	4.5mg/kg IV and 25mg/kg OG	35	35 (31 – 38)	< 0.0001

Median Survival of an intracranial breast cancer model treated with Control (PBS), non-liposomal doxorubicin (NonL-doxo) versus PEGylated Liposomal Doxorubicin (PLD).

^*P value for NonL-doxo vs. PLD  = 0.0002; p value for NonL-doxo/ABT-888 vs. PLD/ABT-888 = 0.006.

Abbreviations: IV, intravenous; OG, oral gavage.